Investigational Therapy for FUS-ALS Achieves Primary Endpoint in Phase 3 Trial
What happened
The investigational antisense therapy ulefnersen met its primary endpoint in the Phase 3 FUSION trial for FUS-ALS. The drug, which is the second successful antisense therapy after Qalsody (tofersen) for SOD1-ALS, showed significant improvement in a combined measure of function and survival compared to placebo. The ALS Association was an early funder of this technology, and the organization partnered with Project ALS to jointly fund research initiatives.
From prnewswire.com
Why it matters
The successful trial results provide hope for new treatments for FUS-ALS, which is the most common cause of juvenile ALS. The ALS Association also supported an expanded access program run by Columbia University, where the trial was conducted.
From prnewswire.com
Who's involved
- ALS AssociationEarly funder of antisense research into FUS-ALS
- Project ALSPartnered with the ALS Association to jointly fund research initiatives
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ALS AssociationSpeculative
The successful trial outcome might validate the ALS Association's early investment in novel rare disease treatments.
Keep exploring
The entities involved
-
ALS Association
American nonprofit organization
-
Columbia University
private university in New York City, New York, US